SCHEMBL849244

SCHEMBL849244

COC(=O)Cn1ccc2c(C=CS(=O)(=O)N3CCC4(CC3)N=C(C3CCCCC3)NC4=O)cccc21

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTH1R Q03431 6/20 0.42
ATM Q13315 1/20 0.36
MEN1 O00255 5/20 0.34
KMT2A Q03164 5/20 0.34
CALCRL Q16602 1/20 0.34
CRHBP P24387 3/20 0.33
CRHR2 Q13324 3/20 0.33
USP2 O75604 1/20 0.33
APOBEC3A P31941 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
CCKBR P32239 1/20 0.32
RECQL P46063 1/20 0.31
OPRL1 P41146 2/20 0.31
OPRM1 P35372 1/20 0.31
OPRK1 P41145 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL849243 1.00 PTH1R (0.42) PTH1RATMMEN1KMT2ACALCRL
SCHEMBL10291509 0.93 PTH1R (0.41) PTH1RMEN1KMT2ACALCRLCRHBP
SCHEMBL848050 0.91 PTH1R (0.41) PTH1RMEN1KMT2ACALCRLALDH1A1
SCHEMBL848051 0.91 PTH1R (0.41) PTH1RMEN1KMT2ACALCRLALDH1A1
SCHEMBL849756 0.90 PTH1R (0.43) PTH1RCALCRLALDH1A1CCKBRRECQL
SCHEMBL849755 0.90 PTH1R (0.43) PTH1RCALCRLALDH1A1CCKBRRECQL
SCHEMBL848583 0.87 PTH1R (0.42) PTH1RATMCALCRLMAPTCCKBR
SCHEMBL848582 0.87 PTH1R (0.42) PTH1RATMCALCRLMAPTCCKBR
SCHEMBL16302354 0.87 PTH1R (0.40) PTH1RCALCRL
SCHEMBL850261 0.86 PTH1R (0.39) PTH1RCALCRL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2433940-B9 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2015-10-28 EP claimed
EP-2433940-B1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2014-09-24 EP claimed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 US claimed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 EP claimed
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 US disclosed
US-20160016956-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-21 US disclosed
EP-2433940-B9 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2015-10-28 EP disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 US disclosed
EP-2433940-B1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2014-09-24 EP disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 US disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 PTH1R 1869/4885ATM 719/4885MEN1 276/4885
US-20160016956-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 PTH1R 1869/4885ATM 719/4885MEN1 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.